At Geistek Pharmaceuticals, we leverage our operational experience, scientific expertise, and innovative tools to deliver high-quality results for sponsors and sites. With central, bioanalytical, and specialty labs strategically located in key global regions including the US, Singapore, China, and Ireland, we ensure accessibility and efficiency in laboratory services. All our laboratories are CAP accredited and comply with GCP or GLP standards.
Our Digital Pathology Solution revolutionizes anatomic pathology for modern clinical trials. Built on globally harmonized histopathology practices, it incorporates our proprietary image data platform, MIRA (Medical Image Review and Analysis). Seamlessly integrated with our global LIMS, this end-to-end offering optimizes central pathology review to support complex trial designs.
We are proud to announce the opening of our new Beijing location for Lab Services. This facility, spanning 950 square meters, supports global drug development and brings together ICON’s clinical research and other staff under one roof. Initially offering a range of testing services such as hematology, chemistry, urinalysis, and more, we will expand our capabilities to include specialty lab testing like histopathology, PCR, slide imaging, and ELISA by the end of 2021. Future plans also include accommodating bioanalytical lab capacity.
At Geistek Pharmaceuticals, we prioritize delivering an improved experience through our integrated project management, communication, and risk management processes. We focus on efficiency in study design, ensuring effective setup, management, and closure. Our services are built upon collaboration with the industry’s most respected health outcomes organizations, enabling cost containment and budget management for your projects.
Partner with Geistek Pharmaceuticals for comprehensive laboratory services and innovative solutions that drive efficiency, quality, and success in your clinical trials.
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment